Switzerland / 5 Trends in Swiss Biotech
While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022…
Since its founding in 1943, the Swiss Tropical Institute (STI), now Swiss Tropical and Public Health Institute (Swiss TPH) has become a world-renowned Institution for teaching, research and services in the field of International Health Development.
The multi- and cross-disciplinary activities and experience of scientific laboratory studies, conceptual clinical work and practical transfer of technical expertise to health system planning and programmes in local, national and partner countries are the building blocks of the Swiss TPH´s success.
Today over 700 colleagues from 40 nations work worldwide for the Swiss TPH in research, teaching and service provision with the single goal to facilitate and contribute to health development worldwide with a strong focus on low and middle income countries.
As an associate institute of the University of Basel, the Swiss TPH takes part in teaching within the medical, philosophy, natural sciences, and historical philosophy faculties, as well as is engaged in post-graduate education and advanced training on national and international levels.
Contact
Swiss Tropical and Public Health Institute
P.O. Box
4002 Basel
Main Secretariat & Travel Clinic:
Socinstrasse 57
4051 Basel
Phone +41 61 284 81 11
While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022…
After seven years at the helm of the pharma industry’s biggest global trade group, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Thomas Cueni is retiring. Having played a…
Gavi, the world’s largest vaccine-focused public-private partnership has a new leader. Pakistani Senator Dr Sania Nishtar has officially assumed the role of CEO following a period of leadership uncertainty for…
The biggest pharma news from Switzerland, including the industry’s cautious reaction to a new free trade deal with India; the drop in Roche’s share prices; Novartis’ acquisiton of MorphoSys, and…
For the Swiss Agency for Therapeutic Products (Swissmedic), one of the world’s leading regulatory authorities, 2023 was an important year. Not only did the agency gain recognition from the World…
Obesity is pharma’s new El Dorado. Following the spectacular market success and sky-high sales projections of next-generation obesity treatments, many actors – both large and small – are looking to…
Every year, the world’s top business and political leaders converge on the ski village of Davos, Switzerland for the World Economic Forum meeting. Read on for some of the key…
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…
Ahead of the 78th session of the United Nations General Assembly (UNGA78), IFPMA Director General Thomas Cueni underscores the need for pandemic preparedness plans to support innovation and equity. Global…
Regular contributor Brendan Shaw* casts his eye over the recently announced 2023 WHO Essential Medicines List, how it reflects growing pharmaceutical innovation, and why maintaining a ‘seat at the table’…
Following the appointment of new boards at the US innovative pharma industry body PhRMA, and its European counterpart EFPIA, it is global group the IFPMA’s turn to reveal a new…
At this year’s Swiss Biotech Day, the Swiss Biotech Association celebrated its 25 years of existence and proved the ability of the sector to weather geopolitical disruptions and funding challenges…
See our Cookie Privacy Policy Here
